Sutro Biopharma (STRO) stock falls as the company announces portfolio review, CEO appointment and headcount reduction. Read ...

Fintel reports that on March 14, 2025, Wedbush downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Outperform ...

Fintel reports that on March 14, 2025, Citizens Capital Markets downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) ...

Sutro Biopharma, a Bay Area oncology biotech company, is laying off around half its staff, switching up its leadership team ...

John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

BofA downgraded Sutro Biopharma (STRO) to Underperform from Buy with a price target of $1, down from $11, following the company’s announcement ...

MoonLake, a clinical-stage biopharma company developing immunology therapeutics, was created by an April 2022 merger with ...

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or ...

Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Sutro completed its review as it widened its loss and posted lower revenue in 2024. The company posted a loss of $227.5 million last year, compared with a loss of $106.8 million in 2023. On a ...

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith ...